New treatment options for irritable bowel syndrome with predominant diarrhea

2016 ◽  
pp. 1
Author(s):  
H. Christian Weber
Keyword(s):  
Irritable Bowel Syndrome ◽  
Treatment Options ◽  
New Treatment ◽  
Irritable Bowel

scholarly journals Irritable bowel syndrome: the problem and the problem of treating it – is there a role for probiotics?

2014 ◽  
Vol 73 (4) ◽  
pp. 470-476 ◽  
Author(s):  
Antonieta R. Santos ◽  
P. J. Whorwell
Keyword(s):  
Irritable Bowel Syndrome ◽  
Therapeutic Potential ◽  
Medical Profession ◽  
Treatment Options ◽  
Bowel Dysfunction ◽  
Poor Quality ◽  
New Treatment ◽  
Irritable Bowel ◽  
Different Strains ◽  
The Impact

The aim of this review is to highlight the impact of irritable bowel syndrome (IBS) in those patients who consult the medical profession and examine the therapeutic potential of probiotics in this condition, where there is a strong need for new treatment options. Traditionally, IBS is frequently regarded as a trivial condition which is certainly not life threatening and mainly psychological in origin. However, these preconceptions are misplaced, as in some patients the condition can be devastating with the pain being as severe as that of childbirth coupled with incapacitating bowel dysfunction. In addition, patients suffer from a variety of non-colonic symptoms such as low backache, constant lethargy, nausea and genito-urinary problems, all of which lead to these patients having extremely poor quality of life. Unfortunately, the treatment of IBS is very unsatisfactory with only one new medication being developed for this condition in the last 25 years. It is now recognised that IBS is a multifactorial condition with symptoms being triggered by a variety of factors, some of which appear to be influenced by probiotics, resulting in speculation that they may have therapeutic potential in this condition. There have been over thirty controlled clinical trials of probiotics in IBS with approximately two-thirds of these studies showing evidence of an improvement in symptoms. However, not all probiotics appear to be effective with different symptoms being improved by different strains and some improving symptoms more than others. Consequently, the ideal probiotic for the treatment of IBS has yet to be defined, but the evidence is good enough to encourage further research with the aim of identifying an optimal strain or strains.

Irritable Bowel Syndrome with Diarrhea

2018 ◽  
Author(s):  
Judy Nee ◽  
Jacqueline L. Wolf
Keyword(s):  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Abdominal Pain ◽  
Treatment Options ◽  
Clinical Manifestations ◽  
Signs And Symptoms ◽  
Treatment Modalities ◽  
Dietary Advice ◽  
Emerging Therapies ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is a complex, functional gastrointestinal condition characterized by abdominal pain and alteration in bowel habits without an organic cause. One of the subcategories of this disorder is IBS with diarrhea (IBS-D). Clinically, patients who present with more than 3 months of abdominal pain or discomfort associated with an increase in stool frequency and/or loose stool form are defined as having IBS-D. This review addresses IBS-D, detailing the epidemiology, etiology and genetics, pathophysiology and pathogenesis, diagnosis, clinical manifestations and physical examination findings, differential diagnosis, treatment, emerging therapies, complications, and prognosis. Figures show potential mechanisms and pathophysiology of IBS, IBS-D suspected by clinical assessment and Rome III criteria, pharmacologic and nonpharmacologic treatment options, potential mechanisms of action of probiotics, and potential treatment modalities. Tables list the Rome criteria for IBS, alarm signs and symptoms suggestive of alternative diagnoses, IBS criteria, differential diagnosis of IBS-D, dietary advice options for IBS-D, and alternative and emerging therapies in IBS-D. This review contains 5 figures, 6 tables and 42 references KEYWORDS: IBS-D, eluxadoline, rifaximin, probiotics, bloating, antidepressants, bile acid malabsorption, microscopic colitis, celiac

scholarly journals Socioeconomic Impact of Irritable Bowel Syndrome in Canada

2001 ◽  
Vol 15 (suppl b) ◽  
pp. 8B-11B ◽  
Author(s):  
Michel Boivin
Keyword(s):  
Health Care ◽  
Irritable Bowel Syndrome ◽  
Health Care Services ◽  
Financial Burden ◽  
Treatment Options ◽  
Indirect Costs ◽  
The United States ◽  
Physician Patient Relationship ◽  
Intangible Costs ◽  
Irritable Bowel

Irritable bowel syndrome (IBS) is the most common functional gastroenterological disorder reported to physicians. In Canada, its prevalence is about 6%. In the United States and the United Kingdom, the prevalence is estimated to be closer to 15%. Patients with IBS tend to make extensive use of health care services, even though a high percentage of them do not seek medical advice. The costs of IBS are a large expenditure of scarce resources. These costs can be divided into several categories: direct, indirect and intangible costs. The direct costs, associated with the diagnosis and treatment, are largely sustained by the health care system. The indirect costs are related to the production losses due to morbidity, and intangible costs are associated with the pain, suffering and alteration in the patient’s quality of life. The condition is a diagnosis of exclusion, and treatment, although beneficial, is rarely curative. The general treatment approach stresses the importance of a good physician-patient relationship. Exploring the nature of the expenses associated with IBS and understanding how treatment options may affect these costs are essential to reducing its financial burden.

Drug Treatment Options for Irritable Bowel Syndrome

Drugs & Aging ◽  
2001 ◽  
Vol 18 (3) ◽  
pp. 201-211 ◽  
Author(s):  
Rebecca C. Dunphy ◽  
G. Nicholas Verne
Keyword(s):  
Irritable Bowel Syndrome ◽  
Drug Treatment ◽  
Treatment Options ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document